Stevard LLC Has $873,000 Stake in Moderna, Inc. (NASDAQ:MRNA)

Stevard LLC reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 6.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 7,350 shares of the company’s stock after selling 501 shares during the quarter. Moderna makes up 0.8% of Stevard LLC’s investment portfolio, making the stock its 21st largest holding. Stevard LLC’s holdings in Moderna were worth $873,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MRNA. Ashton Thomas Private Wealth LLC bought a new stake in Moderna during the second quarter valued at about $26,000. Ogorek Anthony Joseph NY ADV bought a new stake in Moderna during the 4th quarter valued at approximately $27,000. Cedar Wealth Management LLC grew its holdings in Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after buying an additional 90 shares during the last quarter. Westside Investment Management Inc. acquired a new stake in Moderna in the 1st quarter valued at approximately $32,000. Finally, Family Firm Inc. bought a new position in Moderna in the 2nd quarter worth approximately $33,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Performance

NASDAQ MRNA opened at $68.28 on Friday. The company has a 50 day moving average of $95.06 and a 200-day moving average of $111.79. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $170.47. The firm has a market cap of $26.17 billion, a price-to-earnings ratio of -4.36 and a beta of 1.67. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter last year, the company posted ($3.62) EPS. The company’s quarterly revenue was down 29.9% compared to the same quarter last year. On average, equities analysts forecast that Moderna, Inc. will post -9.52 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on MRNA shares. Piper Sandler lowered their price objective on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday. Barclays dropped their price objective on shares of Moderna from $168.00 to $155.00 and set an “overweight” rating on the stock in a report on Friday, August 2nd. Evercore ISI reiterated an “in-line” rating and issued a $120.00 target price on shares of Moderna in a research note on Thursday, June 27th. Jefferies Financial Group cut Moderna from a “buy” rating to a “hold” rating and cut their price target for the company from $120.00 to $65.00 in a report on Friday. Finally, Oppenheimer lowered Moderna from an “outperform” rating to a “market perform” rating in a report on Friday. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Moderna has a consensus rating of “Hold” and a consensus price target of $108.53.

Insider Activity

In related news, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $138.16, for a total value of $2,072,400.00. Following the completion of the sale, the president now directly owns 1,457,089 shares in the company, valued at $201,311,416.24. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $138.16, for a total value of $2,072,400.00. Following the completion of the sale, the president now owns 1,457,089 shares of the company’s stock, valued at approximately $201,311,416.24. The disclosure for this sale can be found here. Insiders have sold 108,158 shares of company stock valued at $13,239,712 over the last 90 days. 15.70% of the stock is owned by company insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.